Review of Strategic Shareholdings Based on Cost of Capital and Benefits
First written in FY2019. 7 of 8 entries say "Advanced", first in FY2020. Latest entry: 2026-05-22.
- 2026-05-22AdvancedPresentation on financial results
「Reducing Cross-Shareholdings」
キャッシュアロケーションにおいて、政策保有株式および投資有価証券の圧縮を資金源の一つとして明示した。 - FY2025AdvancedAnnual report
「The Company acquired 1 unlisted shareholding and 1 shareholding other than unlisted shares, and changed the purpose of holding shares in Resona Holdings, Inc. and Mitsubishi UFJ Financial Group, Inc. to investment purposes.」
While acquiring 2 strategic shareholdings for collaboration purposes, the Company changed the purpose of holding 2 financial institution shareholdings to investment purposes and designated shares whose holding had diminished in significance for consideration of sale. - FY2024AdvancedAnnual report
「Holdings whose number of shares increased during the fiscal year Unlisted shares 3 377,830 Because the Company determined that collaboration with venture companies in the fields of regenerative medicine, drug discovery and lab sharing would contribute to expanding its business」
The Company acquired 3 unlisted shareholdings in the fields of regenerative medicine, drug discovery and lab sharing and recorded a total acquisition cost of ¥377 million. This represents a specific investment reflecting the business benefits of strategic shareholdings. - FY2023AdvancedAnnual report
「In addition, at least once a year, the Board of Directors scrutinizes each listed strategic shareholding, including its purpose, whether the benefits and risks associated with holding it are commensurate with the cost of capital, and other factors, and comprehensively reviews whether the holding is appropriate.」
The Company continued the practice of having the Board of Directors review each holding at least once a year and disclosed a change in the classification of a holding following the initial public offering of an unlisted company held during the fiscal year. - FY2023-Q3AdvancedAnnual report
「This was mainly due to a ¥392 million decrease in property, plant and equipment, primarily as a result of depreciation, and a ¥213 million decrease in investment securities, mainly because part of the shares in the company concerned was sold following its listing, among other factors.」
Following the listing of the company concerned, part of its shares was sold. The disclosure describes a specific sale related to the policy for reviewing strategic shareholdings. - FY2021AdvancedAnnual report
「In addition, at least once a year, the Board of Directors scrutinizes each listed strategic shareholding, including its purpose, whether the benefits and risks associated with holding it are commensurate with the cost of capital, and other factors, and comprehensively reviews whether the holding is appropriate.」
The Company explicitly stated that the Board of Directors reviews each holding at least once a year. It also acquired shares in HPC Systems in connection with a business alliance and changed the purpose of holding shares in SMS and Care21 to investment purposes. - FY2020AdvancedAnnual report
「At least once a year, the Board of Directors scrutinizes each listed strategic shareholding, including its purpose, whether the benefits and risks associated with holding it are commensurate with the cost of capital, and other factors, and comprehensively reviews whether the holding is appropriate.」
The Company specified the process under which the Board of Directors reviews each strategic shareholding at least once a year against the cost of capital. - FY2019First statedAnnual report
「The Company periodically reviews each individual holding from the perspectives of the relationship between the benefits and risks associated with holding the shares and the cost of capital, as well as business advantages.」
The Company first explicitly stated its policy of periodically reviewing each strategic shareholding based on its benefits, risks, cost of capital and business advantages.